194 related articles for article (PubMed ID: 35181017)
1. Carcinosarcoma arising from high-grade serous carcinoma of the ovary without estrogen receptor, WT-1, and PAX8 immunoreactivity.
Harada N; Nobuhara I; Haruta N; Higashiura Y; Fujii H; Yamao K; Shimada K
Taiwan J Obstet Gynecol; 2022 Jan; 61(1):110-114. PubMed ID: 35181017
[TBL] [Abstract][Full Text] [Related]
2. Atypical sigmoid metastasis from a high-grade mixed adenocarcinoma of the ovary.
Zighelboim I; Broaddus R; Ramirez PT
Gynecol Oncol; 2004 Sep; 94(3):850-3. PubMed ID: 15350388
[TBL] [Abstract][Full Text] [Related]
3. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
4. Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma.
Rekhi B; Deodhar KK; Menon S; Maheshwari A; Bajpai J; Ghosh J; Shylasree ST; Gupta S
APMIS; 2018 Jan; 126(1):45-55. PubMed ID: 29266433
[TBL] [Abstract][Full Text] [Related]
5. Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon.
Boyd C; McCluggage WG
Am J Surg Pathol; 2012 Mar; 36(3):368-75. PubMed ID: 22082603
[TBL] [Abstract][Full Text] [Related]
6. [Origin of ovarian epithelial inclusions and its relationship with the development of low-grade serous carcinoma].
Xiang L; Li J; Wang LJ; Zheng WX; Kong BH
Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):729-35. PubMed ID: 22321344
[TBL] [Abstract][Full Text] [Related]
7. Ovarian serous carcinoma associated with a distinct "corded and hyalinized" pattern.
Estrella JS; Wolf JK; Deavers MT
Arch Pathol Lab Med; 2013 Feb; 137(2):275-9. PubMed ID: 23368871
[TBL] [Abstract][Full Text] [Related]
8. Ovarian carcinoma recurring as carcinosarcoma.
Moritani S; Moriya T; Kushima R; Sugihara H; Harada M; Hattori T
Pathol Int; 2001 May; 51(5):380-4. PubMed ID: 11422797
[TBL] [Abstract][Full Text] [Related]
9. Value of PAX8 and WT1 Immunostaining in Confirming the Ovarian Origin of Metastatic Carcinoma in Serous Effusion Specimens.
Zhao L; Guo M; Sneige N; Gong Y
Am J Clin Pathol; 2012 Feb; 137(2):304-9. PubMed ID: 22261458
[TBL] [Abstract][Full Text] [Related]
10. Pair Box 8 (PAX8) protein expression in high grade, late stage (stages III and IV) ovarian serous carcinoma.
Mhawech-Fauceglia P; Wang D; Samrao D; Godoy H; Ough F; Liu S; Pejovic T; Lele S
Gynecol Oncol; 2012 Oct; 127(1):198-201. PubMed ID: 22705448
[TBL] [Abstract][Full Text] [Related]
11. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
Yalcin I; Meydanli MM; Turan AT; Taskin S; Sari ME; Gungor T; Akbayir O; Ayhan A
Int J Clin Oncol; 2018 Apr; 23(2):329-337. PubMed ID: 29143144
[TBL] [Abstract][Full Text] [Related]
12. Synchronous bilateral primary ovarian cancer with right endometroid carcinoma and left high-grade serous carcinoma: a case report and literature review.
Fujimori M; Takahashi T; Furukawa Y; Takanashi A; Iizawa Y; Jimbo M; Soeda S; Fujimori K; Takeichi K
BMC Womens Health; 2022 Apr; 22(1):103. PubMed ID: 35382809
[TBL] [Abstract][Full Text] [Related]
13. Pax8: a marker for carcinoma of Müllerian origin in serous effusions.
Tong GX; Devaraj K; Hamele-Bena D; Yu WM; Turk A; Chen X; Wright JD; Greenebaum E
Diagn Cytopathol; 2011 Aug; 39(8):567-74. PubMed ID: 20607683
[TBL] [Abstract][Full Text] [Related]
14. Serous carcinoma of the ovary with squamous differentiation: a case report and a literature review.
Roberts DE; Lombard CM
Int J Gynecol Pathol; 2013 Sep; 32(5):459-63. PubMed ID: 23896710
[TBL] [Abstract][Full Text] [Related]
15. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas.
Nonaka D; Chiriboga L; Soslow RA
Am J Surg Pathol; 2008 Oct; 32(10):1566-71. PubMed ID: 18724243
[TBL] [Abstract][Full Text] [Related]
16. Loss of PAX8 in high-grade serous ovarian cancer reduces cell survival despite unique modes of action in the fallopian tube and ovarian surface epithelium.
Rodgers LH; Ó hAinmhire E; Young AN; Burdette JE
Oncotarget; 2016 May; 7(22):32785-95. PubMed ID: 27129161
[TBL] [Abstract][Full Text] [Related]
17. Ovarian carcinosarcoma associated with bilateral tubal intraepithelial carcinoma: a case report.
Brustmann H
Int J Gynecol Pathol; 2013 Jul; 32(4):384-9. PubMed ID: 23722511
[TBL] [Abstract][Full Text] [Related]
18. Utility of paired box gene 8 (PAX8) expression in fluid and fine-needle aspiration cytology: an immunohistochemical study of metastatic ovarian serous carcinoma.
McKnight R; Cohen C; Siddiqui MT
Cancer Cytopathol; 2010 Oct; 118(5):298-302. PubMed ID: 20572292
[TBL] [Abstract][Full Text] [Related]
19. The value of PAX8 and WT1 molecules in ovarian cancer diagnosis.
Liliac L; Carcangiu ML; Canevari S; Căruntu ID; Ciobanu Apostol DG; Danciu M; Onofriescu M; Amălinei C
Rom J Morphol Embryol; 2013; 54(1):17-27. PubMed ID: 23529305
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors.
Yasunaga M; Ohishi Y; Oda Y; Misumi M; Iwasa A; Kurihara S; Nishimura I; Okuma E; Kobayashi H; Wake N; Tsuneyoshi M
Hum Pathol; 2009 Jul; 40(7):965-74. PubMed ID: 19269675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
